MI Tumor Seek Hybrid

Casandra

Casandra Test Code CA12210Version 1 (DRAFT)

Performing Lab

Lab Caris Life SciencesLab Test ID N/A

Clinical Use

Use

MI Tumor Seek Hybrid is a laboratory developed test (LDT) that performs high-throughput Next-Generation Sequencing (NGS) to capture both DNA and RNA, combining Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) of over 23,000 genes. It provides a comprehensive molecular blueprint to guide clinical decisions, helping to confirm diagnosis and optimize therapy selection using predictive AI signatures like Caris GPSai and FOLFIRSTai.

Special Instructions

The test provides results with therapy associations, notes on potential benefit or lack of benefit from therapies, and a pre-defined set of cancer-type relevant biomarkers. Important information from Caris pathologists and molecular geneticists is included in the report.

Limitations

The NGS process requires specific sample conditions, including a minimum of 20% tumor nuclei in specimens. The successful testing rate might be impacted by small tumor samples or low-quality specimens.

Test Details

Methodology

NGS

Biomarkers

Whole Exome Sequencing (WES) analyzes over 23,000 genes for single nucleotide variants (SNVs), insertions and deletions (InDels), copy number alterations (CNAs), karyotyping, and viruses.

NGS